NCT04051502CompletedEarly phase 1
ICG-Enabled Mapping of Ovarian Sentinel Lymph Nodes: A Feasibility Study
Source: ClinicalTrials.gov · Last updated 17 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to find out how well ovarian sentinel lymph nodes (SLNs) can be identified with indocyanine green (ICG) dye during risk-reducing ovarian surgery.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 5 Aug 2019
- Start date
- 5 Aug 2019
- Primary completion date
- 8 Dec 2025
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Ovarian cancer
- NCT number
- NCT04051502
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 48
- From 5 Aug 2019 to the primary completion date, 8 Dec 2025
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or current history of uterine, cervical, peritoneal, or vulvovaginal malignancy
- Ongoing anticancer therapy
- Prior bilateral oophorectomy
Other illness
- Current non-GYN primary malignancy
- Known severe anaphylactic iodide allergy
- Known history of cirrhosis or other chronic liver disease, or women with hepatic dysfunction.
Lab values
- Elevated transaminases (ALT, AST) and/or Alk Phos will be evaluated by the treating physician on a case by case basis.
Who the study is looking for
- Women undergoing surgery with the Gynecology Service at MSK.
- Women undergoing surgery for an adnexal mass without pre-operative suspicion of high stage disease, with or without a hysterectomy
- °For this protocol, "suspected high stage disease" will be defined as any patient with radiologic or clinical evidence of ovarian cancer which has spread outside of the ovary. Thus, only patients with an adnexal mass, or bilateral adnexal masses, are eligible.
- Women in whom MIS surgery is converted to a laparotomy will not be excluded as both surgical approaches, MIS and open, will be utilized.
- Women \>/= 18 years of age
- Able to provide informed consent
- Albumin levels within normal range
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan Kettering Basking Ridge (Consent Only) Coordinator of this site? Confirm its status | Basking Ridge | United States | Unknown status |
| Memorial Sloan Kettering Commack (Consent only) Coordinator of this site? Confirm its status | Commack | United States | Unknown status |
| Memorial Sloan Kettering Westchester (Consent only) Coordinator of this site? Confirm its status | Harrison | United States | Unknown status |
| Memorial Sloan Kettering Monmouth (Consent Only) Coordinator of this site? Confirm its status | Middletown | United States | Unknown status |
| Memorial Sloan Kettering Bergen (Consent Only) Coordinator of this site? Confirm its status | Montvale | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Memorial Sloan Kettering Nassau (Consent Only) Coordinator of this site? Confirm its status | Uniondale | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.